Dr. Ramesh Hariharan’s career of 18 years spans a range of subspecialties, including basic research, strategic management consulting, and marketing. At GE’s Basic Research Center, he was nominated as the Best Young Scientist for his innovations, which included the discovery of a new molecule that was commercialized to enable higher data densities in rewritable DVDs, and a novel process for agglomerating nanoparticles. At McKinsey, he served biotech, pharma, medical device, diagnostics, and private equity leaders in the U.S., Germany, and the U.K., tackling a wide range of business issues such as product launches, market expansion, life cycle strategies, and business turnarounds. Dr. Hariharan then held marketing leadership positions in Oncology, Women’s Health, and Vaccines at Novartis, Abbott/AbbVie and Biotheranostics. Most recently at Biotheranostics, he drove the successful commercial turnaround and relaunch of Breast Cancer Index and CancerTYPE ID including repositioning, branding, messaging, and targeted promotions to medical oncologists and patients. He received a bachelor’s degree in chemical engineering from IIT Bombay, a Ph.D. in chemical engineering from Princeton University, and an M.B.A. from MIT Sloan School of Management.
Advances in molecular pathology and hereditary cancer assays have led to a new understanding of breast cancer classification systems, allowing for precision thera-py using molecular tumor signatures that guide both systemic treatments and per-sonalized radiotherapy. The goal is to minimize overtreatment and treatment-associated morbidity for patients while preventing progression and recurrence. This session will focus on the current state of progress in these pursuits and discuss the challenges including prior authorization issues and the growing size of assay pan-els.